The long-term benefits of CIML NK cells have been proven in a mouse model of multiple myeloma, in which IL-12/15/18-stimulated NK cells were able to reduce tumor burden in bone marrow after 7 days, while the treatment with IL-15-stimulated NK cells failed16. The gene discussed is IL15; the disease is plasma cell myeloma.